Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $15.69, but opened at $16.34. Telix Pharmaceuticals shares last traded at $16.66, with a volume of 27,367 shares.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the stock. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday. HC Wainwright initiated coverage on shares of Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price objective on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th.
Read Our Latest Report on TLX
Telix Pharmaceuticals Price Performance
The company's fifty day moving average price is $16.68 and its 200 day moving average price is $16.96. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99.
Institutional Trading of Telix Pharmaceuticals
A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. ABC Arbitrage SA bought a new stake in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
